Evidence review

Tesamorelin for Postherpetic Neuralgia: Evidence Review

Posted Jun 29, 2026 · Updated Jul 17, 2026 · 2 min read

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why Tesamorelin might help you

Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

Tesamorelin → GH axis / visceral fat

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

Scientific sources catalogued (PubMed, trials, reviews): 4
Claims tagged human evidence: 1
Claims tagged preclinical (animal/lab): 2
Claims tagged anecdotal: 0
Reddit posts catalogued: 0
X posts catalogued: 0
Other anecdote sources (YouTube, Instagram, etc.): 0
Total sources in chain: 4

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.3 / 1.00 — low — animal and anecdote heavy

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (source s1)

Ongoing trial focused on PNI, not PHN.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

PubMed.gov

Study

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Ongoing trial focused on PNI, not PHN.

2026-06-29 23:15s1 · #0bb8ee52ed18

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (source s2)

Details trial aims for nerve recovery.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Details trial aims for nerve recovery.

2026-06-29 23:15s2 · #5cf2d75bebd4

Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair (source s3)

Rat study on GH for nerve repair.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

PubMed.gov

Study

Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair

Rat study on GH for nerve repair.

2026-06-29 23:15s3 · #7a65c15798ff

Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration (source s4)

Review of GH mechanisms in nerve injury.

Evidence type: Published research.

PubMed.gov

Study

Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration

Review of GH mechanisms in nerve injury.

2026-06-29 23:15s4 · #9063649e77ac

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Evidence · 4 sources · swipe →chain 9063649e77ac · verify chain · provenance

1 / 4

PubMed.gov

Study

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Ongoing trial focused on PNI, not PHN.

2026-06-29 23:15s1 · #0bb8ee52ed18

PubMed.gov

Study

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Details trial aims for nerve recovery.

2026-06-29 23:15s2 · #5cf2d75bebd4

PubMed.gov

Study

Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair

Rat study on GH for nerve repair.

2026-06-29 23:15s3 · #7a65c15798ff

PubMed.gov

Study

Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration

Review of GH mechanisms in nerve injury.

2026-06-29 23:15s4 · #9063649e77ac

Evidence ledger 4 · tier-ranked · API

preclinical

GH treatment in rats after sciatic nerve transection increased axon/Schwann cell density and improved functional measures.

sources: s3

mechanistic

GH/IGF-1 therapies show multi-modal effects on nerve regeneration and muscle preservation in peripheral nerve injury reviews.

sources: s4

humanlow confidence

Ongoing Phase 2 trial NCT03150511 tests tesamorelin after peripheral nerve injury repair for axonal regeneration and functional recovery.

sources: s2

preclinicallow confidence

No human trials test tesamorelin specifically in postherpetic neuralgia.

sources: s1

Model review1 contributions · 1 modelExpand the recursive review layer

1 / 1

grok/grok-4.3writer

redraft2026-06-29 23:15

Tesamorelin for Postherpetic Neuralgia: Evidence Review · 4 claims · 4 sources

inspect — what it was prompted & output

prompted with

(default writer prompt)

input: Write a data-first, evidence-graded article: Tesamorelin for Postherpetic
Slug: tesamorelin-postherpetic
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"tesamorelin","name":"Tesamorelin"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerati

it output

{
  "slug": "tesamorelin-postherpetic",
  "title": "Tesamorelin for Postherpetic Neuralgia: Evidence Review",
  "body": "## What's breaking down\n\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\n\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n\n- **Tesamorelin** → GH ax

bdc9116903e37af9

Machine verification: /api/articles/tesamorelin-postherpetic/contributions

Ask this article · 6 suggested prompts

topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (preclinical tier): "GH treatment in rats after sciatic nerve transection increased axon/Schwann cell density and improved functional measures."?

ask tesamorelin-postherpetic claim c3 · paste includes §SELF

What does the ledger say about this (mechanistic tier): "GH/IGF-1 therapies show multi-modal effects on nerve regeneration and muscle preservation in peripheral nerve injury reviews."?

ask tesamorelin-postherpetic claim c4 · paste includes §SELF

What does the ledger say about this (human tier): "Ongoing Phase 2 trial NCT03150511 tests tesamorelin after peripheral nerve injury repair for axonal regeneration and functional recovery."?

ask tesamorelin-postherpetic claim c2 · paste includes §SELF

What does the ledger say about this (preclinical tier): "No human trials test tesamorelin specifically in postherpetic neuralgia."?

ask tesamorelin-postherpetic claim c1 · paste includes §SELF

For my medical situation, what can you answer from your catalogue about Tesamorelin for Postherpetic Neuralgia: Evidence Review — and what would you need me to tell you first?

ask tesamorelin-postherpetic condition gaps · paste includes §SELF

What good and bad outcomes are documented for Tesamorelin for Postherpetic Neuralgia: Evidence Review (studies vs anecdotes)?

ask tesamorelin-postherpetic good bad experiences · paste includes §SELF

What's breaking down

Why Tesamorelin might help you

How these fit together

What the evidence actually shows

What scientists say

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (source s1)

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (source s2)

Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair (source s3)

Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration (source s4)

Connected articles

Related articles